Clinical observation of intravitreal injection of ranibizumab for treatment of choroidal neovascularization

Abstract

Objective To observe the efficacy and safety of intravitreal injection of ranibizumab (Lucentis) for treatment of choroidal neovascularization (CNV).Methods Thirty eyes from 30 patients with CNV diagnosed by clinical examination were enrolled in this choroidal neovascularization study.Follow-up duration varied from 3 to 10 months (mean 7.2 months).The best-corrected visual acuity (BCVA) was obtained using the international standard visual acuity chart (converted into logMAR for statistical analysis).Central retinal thickness (CRT) was measured by optical coherence tomography (OCT).All of patients received intravitreal injection of ranibizumab (0.5mg,0.05ml) and repeated treatments after the one-month follow-up if needed.The changes of BCVA,CRT before and after treatment were observed.Results One month after first injection,the mean CRT was (290.23± 79.16) m,the mean logMAR was 0.62±0.31,which were both significant differences (t =6.11,4.79; P ＜0.05) compared with before treatment.Three months after treatment,the mean CRT was (319.73± 89.05) μm,the mean logMAR was 0.61±0.34,which were also significant differences (t =7.69,5.16; P ＜0.05).The greatest CRT reduction was observed in 1 month after the first injection.NO intravitreal injection-related side effects such as endophthalmitis were observed within the follow-up period.Conclusions Intravitreal injection of ranibizumab is effective and safe,may improve BCVA for treatment of CNV.Observed the changes of CRT may initial guide treatment,facilitate clinical observation. Key words: Choroidal neovascularization/therapy; Antibodies; Monoclonal/therapeutic use; Ranibizumab